Inhibikase Therapeutics Files 2025 Proxy Statement

TL;DR

IKT proxy filed for Jan 3, 2025 meeting - vote on directors & auditors.

AI Summary

Inhibikase Therapeutics, Inc. filed its definitive proxy statement on November 18, 2024, for its 2025 annual meeting of stockholders, which is scheduled for January 3, 2025. The filing outlines the proposals to be voted on by shareholders, including the election of directors and the ratification of the appointment of its independent registered public accounting firm. The company is based in Atlanta, GA, and operates in the biological products sector.

Why It Matters

This filing provides shareholders with crucial information about the company's governance and upcoming votes, impacting their ability to make informed decisions about the company's future direction.

Risk Assessment

Risk Level: medium — Proxy statements are routine filings, but the specific proposals and company performance can introduce medium risk depending on shareholder sentiment and potential changes in leadership or strategy.

Key Numbers

• 2025 — Annual Meeting Year (The proxy statement is for the annual meeting to be held in 2025.)
• January 3 — Meeting Date (The annual meeting of stockholders is scheduled for January 3, 2025.)

Key Players & Entities

• Inhibikase Therapeutics, Inc. (company) — Registrant
• 2025 (date) — Fiscal Year End
• January 3, 2025 (date) — Annual Meeting Date
• November 18, 2024 (date) — Filing Date
• Atlanta, GA (location) — Company Headquarters

FAQ

Key Financial Figures

• $0.001 — d shares of our common stock, par value $0.001 per share (“ common stock &#x201

Filing Documents

• ikt-20241118.htm (DEF 14A) — 771KB
• img36587810_0.jpg (GRAPHIC) — 79KB
• img36587810_1.jpg (GRAPHIC) — 466KB
• 0000950170-24-127941.txt ( ) — 1519KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 23

DESCRIPTION OF COMMON STOCK

DESCRIPTION OF COMMON STOCK 31

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 32 HOUSEHOLDING OF PROXY MATERIALS 34 OTHER BUSINESS 35 STOCKHOLDER PROPOSALS AND NOMINATIONS 35 ANNUAL REPORT ON FORM 10-K AND OTHER INFORMATION 36 INHIBIKASE THERAPEUTICS, INC. 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA, GEORGIA 30339 PROXY STATEMENT The Company’s board of directors (the “ Board of Directors ”) has made this Proxy Statement and related materials available to you on the Internet, or, upon your request, has delivered printed proxy materials to you by mail, in connection with the Board of Directors’ solicitation of proxies for use at a Special Meeting of Stockholders (the “ Special Meeting ”) of Inhibikase Therapeutics, Inc. to be held online on Friday, January 3, 2025, beginning at 4:00 p.m., Eastern Time, and at any postponements or adjournments of the Special Meeting. As a stockholder, you are invited to attend the Special Meeting and are requested to vote on the items of business described in this proxy statement (this “ Proxy Statement ”). ABOUT THE SPECIAL MEETING Why did I receive a notice in the mail regarding the Internet availability of proxy materials instead of a full set of proxy materials? In accordance with rules adopted by the Securities and Exchange Commission (“ SEC ”), we are providing access to our proxy materials over the Internet. Accordingly, we are sending a Notice Regarding Availability of Proxy Materials (the “ Notice ”) to our stockholders of record and beneficial owners as of the Record Date (as defined below). For more information on the Record Date, see “– Who is entitled to vote at the Special Meeting? ”. The mailing of the Notice to our stockholders is scheduled to begin on or about November 22, 2024. All stockholders will have the ability to access the proxy materials and our Annual Re

View Full Filing

View this DEF 14A filing on SEC EDGAR